Search Results

You are looking at 81 - 90 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

... or in a delayed procedure in patients with extranodal extension .” Removed bullet: “Neoadjuvant chemotherapy should be considered the standard (prior to ILND) in patients with ≥4 cm inguinal lymph nodes, if FNA is positive for metastatic penile

Full access

John B. Eifler, Daniel A. Barocas and Matthew J. Resnick

schedules may be individualized based on the EORTC or CUETO risk score. Muscle-Invasive Bladder Cancer Patient Selection for Neoadjuvant Chemotherapy A landmark randomized controlled trial published in 2003 (SWOG-8710) demonstrated that patients

Full access

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou and Anthony L. Zietman

than among those in bladder preservation studies. For example, the median age of patients in the US Intergroup trial comparing cystectomy with or without neoadjuvant chemotherapy was 63 years, 21 whereas that for BC2001 (radiation with

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

Sebag-Montefiore D . Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study . J Clin Oncol 2006 ; 24 : 4664 – 4665 ; author reply 4665–4666 . 88 Bosset JF Calais G Mineur L . Enhanced tumorocidal effect of

Full access

Lauren Nye, Timothy K. Huyck and William J. Gradishar

obtained, which did not suggest distant metastases. Treatment options, including mastectomy, breast-conserving therapy with axillary staging, and neoadjuvant chemotherapy, were discussed extensively with the patient. Throughout the discussion, the patient

Full access

Rolland Betsy a PhD, MLIS, MPH Eschler Jordan b c PhD, MS 7 2018 16 16 7 7 839 839 844 844 10.6004/jnccn.2018.7019 jnccn_16_7_009 Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of

Full access

Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Gabani Prashant a * MD Merfeld Emily a * MD Srivastava Amar J. a MD Weiner Ashley A. b MD, PhD Ochoa Laura L. a RN, PhD Mullen Dan a DDS Thomas

Full access

Matthew C. b c MD, SM Chan Kelvin K. b c d MD, MSc, PhD 03 2020 18 18 3 3 278 278 285 285 jnccn19101 10.6004/jnccn.2019.7362 Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant

Full access

whether CT chest, CT abdomen/pelvis, PET scan, bone scan, and brain imaging studies were ordered; reason for ordering them; and the time to first treatment with either neoadjuvant chemotherapy or surgery. Results: At least one staging study was ordered

Full access

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg and Gregory A. Vidal

ductal carcinoma of the breast in 2007. She received neoadjuvant chemotherapy with dose-dense doxorubicin, cyclophosphamide, and paclitaxel, and subsequently underwent a lumpectomy and axillary lymph node dissection showing residual carcinoma. After whole